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In 1943, Kanner described 11 children 
affected by a unique disorder that he 
designated “early infantile autism” (Kan-
ner, 1943). It has since become clear that 
autism is comprised of a clinically hetero-
geneous group of disorders, collectively 
termed “autism spectrum disorders” 
(ASDs), that share common features of 
impaired social relationships, impaired 
language and communication, and lim-
ited range of interests and behavior.
Cognitive impairment is common in 
autism, and ~70% of autistic individu-
als suffer from mental retardation (Fom-
bonne, 1999). Neuropathological studies 
have reported minor and inconsistent 
abnormalities in the autistic brain, but 
recent morphometric analysis has demon-
strated enlargement of the hippocampus 
and amygdala (Schumann et al., 2004). As 
first noted by Kanner, a high prevalence 
of macrocephaly is observed among 
children with ASDs, possibly due to an 
early period of excessive brain growth 
(Courchesne et al., 2004). Remarkably, 
as many as 10% of autistic individuals 
paradoxically exhibit restricted domains 
of normal or even superior skills, termed 
“savant abilities,” on a background of 
cognitive disability (Heaton and Wal-
lace, 2004). Savant syndrome can involve 
excellence in a variety of cognitive or 
artistic domains, but declarative memory 
is most consistently accentuated.
Autism is among the most heritable 
neuropsychiatric disorders, and available 
evidence points to a complex genetic 
basis (Persico and Bourgeron, 2006). 
However, several disorders caused by 
single-gene mutations are associated 
with autism, often accompanied by cog-
nitive impairment (Table 1). In these disor-
ders, a substantial proportion of affected 
individuals meet diagnostic criteria for 
ASDs, reflecting a greatly increased risk 
of autism conferred by the mutation. 
Conversely, a small but significant per-
centage of children presenting with ASDs 
carry mutations in one of these genes. 
Although such monogenic disorders col-
lectively account for a minority of cases 
of autism (10%–15%), the molecular 
alterations in these disorders may identify 
common pathogenic pathways shared by 
ASDs.
The identification of mutations in neu-
roligins as rare genetic causes of autism 
suggested that defects in synaptic func-
tion may be intimately involved in autism 
pathogenesis (Zoghbi, 2003; Persico and 
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Autism is a complex genetic disorder, but single-gene disorders with a high prevalence of autism 
offer insight into its pathogenesis. Recent evidence suggests that some molecular defects in 
autism may interfere with the mechanisms of synaptic protein synthesis. We propose that aberrant 
synaptic protein synthesis may represent one possible pathway leading to autistic phenotypes, 
including cognitive impairment and savant abilities.
Table 1. Single-Gene Disorders with High Rates of Autism
Gene Disorder Rate of Autism Rate in Autism MR Gene Function
FMR1 Fragile X syndrome 15%–30% 2%–5% + Translational repressor
TSC1/2 Tuberous sclerosis complex 25%–60% 1%–4% + Inhibitor of mTOR
PTEN PTEN hamartoma syndrome  
(ASD with macrocephaly) 
ND 1% + Inhibitor of PI3K/mTOR signaling
NF1 Neurofibromatosis type I 4% 0%–4% + Ras GAP
MECP2 Rett’s syndrome 100% 2% + Global transcriptional repressor
UBE3A Angelman’s syndrome 40% 1% + E3 ubiquitin ligase
CACNA1C Timothy’s syndrome 60% <1% + L-type voltage-gated calcium channel (Cav1.2)
NLGN3/4 Familial ASD ND <1% + Synaptic adhesion
NRXN1 Familial ASD ND <1% + Synaptic adhesion
SHANK3 Familial ASD  
(22q13 microdeletion syndrome) 
ND <1% + PSD scaffolding
Several monogenic human disorders are characterized by cognitive impairment and autism. The estimated rate of autism spectrum disorders (ASDs) 
in each disease and the estimated rate of each disease in children with ASDs are indicated (rate of autism and rate in autism, respectively). MR refers 
to the association of mental retardation with each disorder. ND indicates that the prevalence of ASDs among individuals carrying mutations in the 
specified gene has not been determined.
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Bourgeron, 2006). Consistent with this 
view, mouse models of mutations that 
cause ASDs in humans consistently point 
to disrupted synaptic function: excessive 
or diminished excitatory synaptic con-
nectivity (Chao et al., 2007; Hanson and 
Madison, 2007) and alterations in the bal-
ance of excitation and inhibition (Dani et 
al., 2005; Tabuchi et al., 2007). It appears 
that the “autistic neuron” has too many or 
too few, too strong or too weak, excitatory 
synapses relative to the level of inhibition. 
However, mutations in ASDs that directly 
affect synaptic structure are rare. In this 
Essay, we focus on recent insights into 
the function of gene products mutated 
in several other autistic disorders. We 
propose that dysregulation of synaptic 
protein synthesis in these disorders may 
lead to altered synaptic development and 
plasticity and autistic phenotypes.
Aberrant Synaptic Protein Synthesis 
in Autism
The gene products mutated in several 
single-gene disorders associated with 
autism act as negative regulators of protein 
synthesis (Figure 1). Fragile X syndrome 
(FXS) is an X-linked form of mental retar-
dation caused by transcriptional silencing 
of the FMR1 gene (Bagni and Greenough, 
2005). The prevalence of ASDs in FXS is 
reportedly 15%–30%, and conversely, up 
to 5% of children presenting with ASDs 
are found to have FXS. The product of 
the FMR1 gene, the fragile X mental retar-
dation protein (FMRP), binds to specific 
mRNAs and represses their translation. 
FMRP is estimated to interact with more 
than 400 distinct mRNAs (Brown et al., 
2001). Loss of FMRP expression in FXS 
would be expected to cause translational 
derepression of these target mRNAs. 
Indeed, there is a substantial (~20%) and 
anatomically widespread increase in the 
rate of cerebral protein synthesis in the 
Fmr1 knockout mouse, which models the 
silencing of FMRP expression responsible 
for the human disorder (Qin et al., 2005).
Tuberous sclerosis complex (TSC) is an 
autosomal dominant disorder caused by 
mutations in hamartin (TSC1) or tuberin 
(TSC2) (Kwiatkowski and Manning, 2005). 
Central nervous system involvement in 
TSC is characterized clinically by a high 
prevalence of ASDs (25%–60%), cogni-
tive impairment, and epilepsy (Wiznitzer, 
2004). TSC1 and TSC2 form a heterodi-
meric complex with GAP activity against 
the small GTP-binding protein Rheb, 
resulting in inhibition of the mammalian 
target of rapamycin (mTOR) kinase (Fig-
ure 1). More specifically, TSC1/2 inhibit 
the activity of the rapamycin-sensi-
tive mTOR-raptor complex (mTORC1). 
mTORC1, which is activated by a sequen-
tial kinase cascade downstream of phos-
phoinositide-3 (PI3) kinase, is a major 
regulator of cellular growth in mitotic 
cells (Wullschleger et al., 2006). One of 
the principal effector mechanisms of 
mTORC1 is activation of cap-dependent 
translation. Recognition of the 5′ mRNA 
cap by eIF4E, which leads to recruitment 
of eIF4G and the small ribosomal subunit, 
is the key regulatory step in translation ini-
tiation (Richter and Sonenberg, 2005). A 
family of eIF4E-binding proteins, 4E-BPs, 
impedes this process by sequestering 
eIF4E and blocking its association with 
eIF4G. Phosphorylation of 4E-BPs by 
mTORC1 relieves this inhibition, promot-
ing eIF4E release and activation of cap-
dependent initiation. Phosphorylation 
of another mTORC1 substrate, p70 ribo-
somal protein S6 kinase (S6K), also facili-
tates translation. Inactivation of TSC1/2 
in hippocampal neurons upregulates 
mTORC1 activity (Tavazoie et al., 2005; 
Meikle et al., 2007; Ehninger et al., 2008), 
suggesting that loss of TSC1/2 function 
elicits enhanced translation in neurons.
Loss-of-function mutations in another 
negative regulator of PI3K-mTOR signal-
ing, the PTEN phosphatase, have also 
been linked to ASD pathogenesis. PTEN 
antagonizes PI3K-dependent signaling 
by converting the second messenger PIP3 
to PIP2, and loss of PTEN function in neu-
rons leads to heightened mTORC1 activity 
(Kwon et al., 2006). Inactivating mutations 
in PTEN are responsible for several related 
familial hamartoma-tumor syndromes, the 
clinical spectrum of which includes mac-
rocephaly associated with ASDs. Macro-
cephaly occurs in up to 20% of ASD cases, 
and PTEN mutations have been identified 
in ~5% of ASD patients with macrocephaly 
(e.g., Butler et al., 2005). The connection 
between macrocephaly and PTEN muta-
tions is interesting in view of the role of 
the PI3K-mTOR pathway in regulation of 
Figure 1. Neuronal Signaling Pathways in Translational Regulation
The Ras/ERK and PI3K/mTOR signaling pathways couple synaptic activity to the translational machinery 
and play essential roles in protein synthesis-dependent LTP and LTD. These signaling pathways are 
recruited downstream of the activation of NMDA receptors, group I metabotropic glutamate receptors, 
and neurotrophin Trk receptors. Regulation of the availability and activity of the mRNA cap-binding factor 
eIF4E is a primary effector mechanism through which these pathways modulate synaptic protein synthe-
sis. Inactivating mutations in several negative regulators of the ERK and mTOR pathways, including NF1, 
PTEN, and TSC1/2, are responsible for genetic disorders with a high prevalence of cognitive impairment 
and autism. FMRP represses translation of specific target mRNAs, and loss of FMRP expression in fragile 
X syndrome (FXS) leads to cognitive impairment and autism. We hypothesize that loss of the normal con-
straints on synaptic activity-induced protein synthesis may be one of several pathogenic mechanisms 
leading to autism.
cell size, an effect thought to be mediated 
through translational control (Backman 
et al., 2002; Fingar et al., 2002). In mitotic 
cells, activation of this pathway increases 
cell size, whereas inhibition decreases cell 
size. It is not clear to what extent macro-
cephaly in ASD patients may be due to 
increased neuronal size; however, inac-
tivation of either TSC1/2 or PTEN in mice 
causes neuronal hypertrophy and macro-
cephaly (Backman et al., 2002; Meikle et 
al., 2007).
Taken together, the association of 
mutations in FMRP, TSC1/2, and PTEN 
with autism suggests that defects in 
translational repression may represent 
one possible mechanism leading to autis-
tic phenotypes. It will therefore be of 
interest to determine whether defects in 
additional components of such pathways 
might contribute to autism susceptibility.
Translational Control in Synaptic 
Plasticity and Cognition
As in all cells, elaborate mechanisms 
regulate protein synthesis in neurons to 
ensure adaptive responses to a chang-
ing environment (Kelleher et al., 2004b; 
Klann and Dever, 2004; Sutton and Schu-
man, 2006). There is abundant evidence 
for transcriptional regulation by neuronal 
activity and by downstream intracellular 
signals that are integrated in the neuronal 
cell body. However, patterns of activity at 
the thousands of synapses on each neu-
ron dictate where and how this mRNA is 
used to synthesize proteins to fine-tune 
neuronal function. Markers of mRNA 
translation suggest that synaptic activity-
induced protein synthesis occurs locally 
at or near dendritic spines in response to 
the synaptic release of glutamate. Two 
types of postsynaptic glutamate recep-
tor have been implicated in translational 
regulation: the Gq-coupled metabotropic 
glutamate receptors 1 and 5 (mGluR1 
and 5) and the calcium-permeable NMDA 
receptors (NMDARs). In addition to acti-
vating intracellular signaling pathways, 
there is evidence that NMDAR activa-
tion stimulates release of brain-derived 
neurotrophic factor (BDNF), which can 
induce neuronal protein synthesis through 
activation of synaptic TrkB receptors. 
Excitatory synaptic activity drives trans-
lation by activating these receptors, and 
this process is normally held in check 
by negative regulators such as FMRP, PTEN, and TSC1/2. Mutations that cause 
either overactivation of these receptors 
or decreased negative regulation of pro-
tein synthesis knock the system out of 
balance. We propose that a functional 
consequence is synaptic dysfunction that 
may manifest in humans as autism.
Protein synthesis in the neuron has 
been extensively studied in the context 
of memory formation in adults and, more 
recently, experience-dependent cortical 
development. In both contexts, the imme-
diate encoding and storage of information 
do not require protein synthesis. How-
ever, new gene expression is required for 
these changes to endure for longer than 
a few hours. Experimental forms of syn-
aptic plasticity display similar temporal 
and molecular distinctions. Hippocampal 
long-term potentiation (LTP) and long-
term depression (LTD) exhibit persistent 
late phases (L-LTP and L-LTD, respec-
tively) that require new gene expression 
and transient early phases (E-LTP and 
E-LTD, respectively) that are insensitive to 
inhibitors of transcription and translation.
Investigation of the molecular mecha-
nisms mediating this process has high-
lighted the central importance of trans-
lational regulation. The presence of 
mRNAs and polyribosomes in proximity 
to synaptic sites suggested that local 
protein synthesis in dendrites could rap-
idly supply new gene products to acti-
vated synapses. The discoveries that 
BDNF-induced LTP and mGluR-depen-
dent LTD, both of which require protein 
synthesis, can be supported by isolated 
dendrites further suggested a crucial role 
for translational upregulation in response 
to synaptic activity (Kang and Schuman, 
1996; Huber et al., 2000). Comparison of 
the effects of transcriptional and transla-
tional inhibitors, combined with metabolic 
labeling, has shown that establishment of 
L-LTP is mediated by rapid upregulation 
of the translation of pre-existing mRNAs 
(Kelleher et al., 2004a).
Recent work from several groups has 
established that the ERK, MAPK, and 
mTOR signaling pathways couple synap-
tic activity to the translational machinery 
during both protein synthesis-dependent 
LTP and LTD (Figure 1). The ERK path-
way, which is activated downstream of 
NMDAR, mGluR, and TrkB receptors, plays 
important roles in synaptic plasticity and 
memory (Sweatt, 2004). ERK activation is Cell 1required for stimulation of cap-dependent 
translation and phosphorylation of eIF4E, 
4E-BPs, and S6 in hippocampal neurons in 
response to L-LTP induction, NMDAR acti-
vation, and BDNF (Kelleher et al., 2004a). 
Targeted disruption of ERK signaling in the 
hippocampus prevents these translational 
responses and causes selective deficits in 
L-LTP and long-term memory. Inhibition 
of mTORC1 activity in hippocampal neu-
rons attenuates synaptic activity-induced 
translation, 4E-BP phosphorylation, L-LTP, 
and BDNF-induced LTP (Tang et al., 2002; 
Kelleher et al., 2004a). Similarly, activation 
of mGluR1/5 leads to ERK- and mTOR-
dependent increases in eIF4E, 4E-BP, and 
S6 phosphorylation, and inhibition of the 
ERK or mTOR pathways blocks mGluR-
dependent LTD (Gallagher et al., 2004; 
Hou and Klann, 2004; Banko et al., 2006). 
Collectively, these findings support a 
requirement for ERK- and mTOR-regulated 
translation in protein synthesis-dependent 
synaptic plasticity and memory.
Analysis of synaptic plasticity in a 
mouse model of FXS illustrates how loss 
of the normal constraints on neuronal 
translation may give rise to synaptic 
and cognitive impairment. Fmr1 knock-
out mice display a range of phenotypes 
reminiscent of the human disorder. Inter-
estingly, mGluR-dependent LTD, which 
requires translation but not transcrip-
tion for its expression, is significantly 
enhanced in the hippocampus of Fmr1 
knockout mice (Huber et al., 2002). Fur-
ther supporting the view that increased 
translation of FMRP target mRNAs 
underlies this LTD phenotype, hippocam-
pal mGluR-dependent LTD is rendered 
insensitive to translational inhibitors in 
Fmr1 knockout mice (Hou et al., 2006; 
Nosyreva and Huber, 2006). Presumably, 
essential LTD proteins are constitutively 
overexpressed in the absence of FMRP.
What might be the consequence of this 
manifestation of “hyperplasticity” in the 
hippocampus? Recently it was shown 
that inhibitory avoidance learning in rats 
induces LTP in the CA1 region of the hip-
pocampus (Whitlock et al., 2006). In addi-
tion to its role in LTD, mGluR-dependent 
protein synthesis has also been impli-
cated in the reversal of LTP (Zho et al., 
2002). Thus, one might anticipate that a 
manifestation of exaggerated LTD would 
be impaired retention or increased extinc-
tion of inhibitory avoidance memory. This 35, October 31, 2008 ©2008 Elsevier Inc. 403
phenotype has been observed in Fmr1 
knockout mice (Dolen et al., 2007). Thus, 
exaggerated mGluR-dependent protein 
synthesis in the absence of FMRP may 
yield specific patterns of cognitive impair-
ment in adults with FXS.
Cognitive impairment and autism may 
also reflect, at least in part, defects in 
synaptic development and/or devel-
opmental plasticity. Ocular dominance 
plasticity in the developing visual cor-
tex, a commonly studied model for 
experience-dependent rearrangement 
and refinement of synaptic connectivity, 
requires both ERK activation and new 
protein synthesis, suggesting that simi-
lar translational mechanisms contribute 
to synaptic plasticity in the develop-
ing and adult brain (Maffei and Berardi, 
2002; Taha and Stryker, 2002). Studies of 
ocular dominance plasticity in the fragile 
X mouse model again revealed hyper-
plasticity—an exaggerated response to 
visual deprivation (Dolen et al., 2007).
Neuronal activity-induced protein syn-
thesis is crucial for long-lasting modifica-
tions of neural circuits. However, these 
findings in the mouse model of FXS sug-
gest that impairments in synaptic and 
cognitive function can result from too 
much of what is normally a good thing. 
Further evidence that excessive transla-
tion can compromise cognitive function 
comes from mouse models deficient in 
PTEN and TSC1/2 function, in which ele-
vated mTORC1 activity is associated with 
impaired hippocampal memory (Kwon et 
al., 2006; Goorden et al., 2007; Ehninger et 
al., 2008).
Aberrant Synaptic Tagging and 
Capture
To facilitate consolidation of synaptic 
modifications, newly synthesized proteins 
must be targeted specifically to active 
synapses. The phenomenon of synaptic 
tagging and capture suggests that synap-
tic stimulation creates an immobile “tag” 
at active synapses that “captures” essen-
tial protein products (Frey and Morris, 
1997). Induction of L-LTP in one synaptic 
pathway can effectively convert E-LTP to 
L-LTP in a second independent synaptic 
pathway, suggesting that proteins syn-
thesized in response to stimulation of one 
group of synapses are available to other 
stimulated synapses within the same 
neuron. Synaptic tagging and capture are 404 Cell 135, October 31, 2008 ©2008 Elsevalso observed with LTD, and in fact, cross-
capture has been reported between LTP 
and LTD: induction of L-LTP in one synap-
tic pathway can convert E-LTD to L-LTD in 
another pathway, and vice versa (Sajiku-
mar and Frey, 2004). Crosscapture sug-
gests that induction of L-LTP and L-LTD 
may stimulate the synthesis of overlapping 
sets of proteins capable of enabling either 
process, consistent with evidence for the 
use of similar ERK- and mTOR-dependent 
translational mechanisms outlined above. 
In essence, synaptic capture implies that 
the local availability of essential proteins 
is sufficient to promote the consolidation 
of LTP and LTD. If the supply of essential 
proteins is limiting, competition can also 
be observed among groups of tagged 
synapses for consolidation of the accom-
panying synaptic changes (Fonseca et al., 
2004).
From a behavioral standpoint, new 
proteins synthesized during a learning 
episode enable associative and competi-
tive interactions among neighboring syn-
apses experiencing LTP and LTD, and the 
resulting pattern of persistent synaptic 
weight changes is likely to be crucial for 
proper long-term memory representa-
tion (Govindarajan et al., 2006). By alter-
ing the levels and/or identities of avail-
able proteins, dysregulation of neuronal 
protein synthesis would interfere with the 
establishment of appropriate patterns 
of synaptic modification. In particular, 
increased availability of plasticity-related 
proteins would promote consolidation of 
synaptic changes that would otherwise 
be lost. Such inappropriate synaptic con-
solidation would generally be expected to 
compromise the cognitive performance 
of neural circuits, reducing the specific-
ity and signal-to-noise ratio of synaptic 
changes that underlie normal learning. 
It is interesting to consider the possi-
bility that excessive synaptic capture and 
consolidation may in certain situations 
allow for enhanced long-term memory 
formation. Superior declarative memory, 
which depends on the hippocampus, is 
a common feature of savant abilities in 
autistic individuals (Heaton and Wallace, 
2004). Whereas effective memory con-
solidation and retention typically benefit 
incrementally from repeated exposure to 
new information, individuals with savant 
abilities are remarkable in their capacity for 
rapid or “single trial” learning. Thus, in the ier Inc.case of mnemonic savant abilities, exces-
sive protein synthesis could promote rapid 
and efficient synaptic capture and con-
solidation of hippocampal memory traces, 
regardless of their salience, while at the 
same time causing a more generalized 
impairment of cognitive function. In this 
way, cognitive impairment and savant abil-
ities could be two sides of the same coin. 
It will be of interest to determine whether 
mutations causing elevated synthesis or 
abundance of neuronal proteins are asso-
ciated with savant abilities in autism.
Possible Mechanistic Connections 
with Other Autistic Disorders
The functions of gene products mutated 
in other monogenic disorders that over-
lap with autism lead us to speculate 
that overexpression of plasticity-related 
proteins may be one possible molecular 
mechanism underlying autism (Table 1). 
Neurofibromatosis type I is caused by 
inactivating mutations in neurofibromin 
(NF1), a Ras GAP, resulting in upregulation 
of Ras-dependent ERK and mTOR acti-
vation (Dasgupta and Gutmann, 2003). 
Mutations in the E3 ubiquitin ligase UBE3A 
have been identified in Angelman’s syn-
drome, suggesting that ubiquitin-depen-
dent protein turnover may be impaired in 
this disorder, possibly leading to elevated 
synaptic protein levels (Jiang and Beau-
det, 2004). Timothy’s syndrome is caused 
by mutations in the L-type voltage-gated 
calcium channel (VGCC) Cav1.2, which 
impair channel inactivation and prolong 
inward calcium ion currents (Splawski et 
al., 2004). Although the resulting enhance-
ment of calcium ion influx may have pleio-
tropic effects, activation of the ERK path-
way and CREB-dependent transcription 
are major effector mechanisms regulated 
by L-type VGCCs (Dolmetsch et al., 2001). 
The molecular defects in these disorders 
suggest that a common consequence 
may be an overabundance of plasticity-
related proteins.
Rett’s syndrome is caused by loss-of-
function mutations in the methyl-CpG 
binding protein 2 (MeCP2), which can 
function as both a transcriptional activator 
and repressor (Chahrour et al., 2008). In 
rare cases, a Rett-like syndrome can also 
be caused by duplication of the MECP2 
locus, indicating that decreased and 
increased MeCP2 dosage produce similar 
phenotypes. Analysis of mouse models 
either lacking or overexpressing MeCP2 
revealed that neuronal transcription of a 
large number of target genes is decreased 
by loss of MeCP2 function, whereas 
transcription of the same group of target 
genes is increased by gain of MeCP2 
function. Interestingly, the number of excit-
atory hippocampal synapses is decreased 
in mice lacking MeCP2 and increased in 
mice overexpressing MeCP2 (Chao et al., 
2007), indicating that altered transcription 
of MeCP2 target genes, which presum-
ably results in altered synthesis of the 
encoded proteins, produces correspond-
ing changes in synaptic connectivity.
As emphasized above for other autis-
tic disorders, these findings suggest that 
cognitive deficits and autistic features 
arise in the MeCP2 duplication syn-
drome as a result of exaggerated protein 
expression. Conversely, findings from the 
mouse model of Rett’s syndrome suggest 
that inadequate protein expression can 
also produce cognitive impairment and 
autism. Supporting this notion, multidisci-
plinary studies in mice have demonstrated 
that defects in synaptic protein synthesis 
impair hippocampal learning and mem-
ory (Kelleher et al., 2004a; Costa-Mattioli 
et al., 2007). In a recent human genetic 
study, ASD-linked deletion mutations 
affected several genes whose expression 
is stimulated by neuronal activity, further 
arguing that defects in synaptic activity-
induced gene expression contribute to 
ASD pathogenesis (Morrow et al., 2008). 
Based on these observations, we sug-
gest that the performance of neuronal 
networks mediating cognition depends 
on the level of synaptic protein synthesis 
(Figure 2). Deviations in either direction 
from the optimal level of synaptic protein 
synthesis can adversely affect synaptic 
capture and consolidation, and the result-
ing perturbations in synaptic connectivity 
may underlie the development of cogni-
tive impairment and autistic traits. The 
manner in which synaptic properties are 
affected by aberrant protein synthesis is 
likely to depend on the identities of the 
individual proteins whose expression is 
altered.
A parsimonious view of autism patho-
genesis would envision the convergence 
of diverse molecular triggers on a final 
common disease-causing pathway. The 
identification of ASD-linked mutations in 
the synaptic adhesion molecules neuroli-gins 3 and  4 has suggested that synaptic 
abnormalities play a central role in autism 
(Zoghbi, 2003; Persico and Bourgeron, 
2006). Our proposed model provides an 
additional molecular mechanism leading 
to synaptic dysfunction in autism. How 
might defective synaptic adhesion and 
aberrant synaptic protein synthesis pro-
duce a common synaptic phenotype? 
Recent evidence indicates that neuroli-
gins stabilize new synapses and specify 
their functional properties, thereby regu-
lating the balance of excitatory and inhibi-
tory transmission (Chubykin et al., 2007) 
(see Essay by Walsh et al., page 396 of 
this issue). Interestingly, an ASD-linked 
missense mutation in neuroligin 3 shifts 
this balance of excitation and inhibition in 
favor of increased inhibitory drive (Tabu-
chi et al., 2007). Dysregulated protein 
synthesis could similarly alter the balance 
of excitation and inhibition by promoting 
the net strengthening or weakening of 
excitatory relative to inhibitory synapses. 
For example, excessive protein synthesis-
dependent LTD, as observed in the hip-
pocampus of Fmr1 knockout mice, could 
promote a net weakening of excitatory 
relative to inhibitory synapses. Reduced 
excitatory and/or increased inhibitory 
synaptic activity has been observed in 
the hippocampus and neocortex of sev-
eral other mouse models of ASDs, sug-
gesting that an imbalance of excitation 
and inhibition may be a common synap-
tic phenotype underlying autism (Cline, 
2005; Dani et al., 2005; Chao et al., 2007; 
Hanson and Madison, 2007). It remains 
to be seen whether altered protein syn-
thesis-dependent plasticity at excitatory 
and/or inhibitory synapses contributes to 
imbalances of excitation and inhibition in 
mouse models of autism.
Future Directions
Single-gene disorders that increase autism 
risk in humans offer an exciting window 
into autism because they can be mod-
eled in mice. Mouse models for several of 
these disorders display behavioral pheno-
types resembling human autism, including 
impairments in cognition and social inter-
action (Moy et al., 2006). However, it should 
be emphasized that the synaptic pathol-
ogy that yields autistic behavior in humans 
might have distinct effects in other spe-
cies due to differences in brain circuitry. 
Thus, the failure of a single-gene muta-
tion in mice to phenocopy the full spec-
trum of clinical features does not diminish 
the importance of the mouse models to 
reveal pathophysiology and, potentially, 
new treatments. Based on the findings in 
mice discussed above, we hypothesize 
that mutations that lead to excessive or 
dysregulated synaptic protein synthesis 
could be one mechanism contributing to 
autism in humans. One prediction of our 
hypothesis that can be tested in mice is 
that there should be some observable 
commonalities in the synaptic dysfunc-
tion wrought by the loss of FMRP, TSC1/2, 
and PTEN. If our hypothesis proves to be 
correct, approaches to restoring normal 
Figure 2. Bidirectional Alterations in Synaptic Protein Synthesis in Monogenic Disorders
We propose that the performance of neuronal networks mediating cognition is a function of the level of 
synaptic protein synthesis. Increases or decreases in the levels of plasticity-related proteins available to 
active synapses in autistic neurons may cause corresponding changes in synaptic connectivity, compro-
mising network performance and producing cognitive impairment. In several single-gene disorders as-
sociated with autism, such as Fragile X syndrome, levels of synaptic protein availability and connectivity 
are increased, but in Rett’s syndrome these levels are decreased.Cell 135, October 31, 2008 ©2008 Elsevier Inc. 405
levels of protein expression may provide 
a therapeutic strategy for treating these 
disorders, and perhaps mental retardation 
and autism. In the case of FXS, the discov-
ery of enhanced mGluR-dependent LTD 
suggests that inhibition of mGluR activ-
ity may be one way to limit the excessive 
translational response to mGluR activation 
(Bear et al., 2004). Indeed, a range of phe-
notypes displayed by mice lacking Fmr1 
can be rescued by genetic reduction of 
mGluR5 activity (Dolen et al., 2007). Simi-
larly, the mTOR inhibitor rapamycin rescues 
abnormal hippocampal LTP and memory 
in a mouse model of TSC (Ehninger et al., 
2008). Other approaches that restrain the 
activity of the molecular machinery regu-
lating synaptic protein synthesis may have 
therapeutic potential in autism.
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